Evaluation Of The Lipid Lowering Ability And Clinical Safety Of The Joint Using Of Zhibitai Capsule With Atorvastatin

Objective: The aim of this study was to evaluate the effects of the joint using ofZhibitai capsule with atorvastatin and prove the security of strengthen lipid loweringtherapy.Methods:60patients with dyslipidemia of coronary heart disease and other riskdisease were randomly devided into test group（n=30） and contrast group（n=30），and the course of treatment was eight weeks. The test group received480mg of Zhibitaiorally twice daily and20mg of atorvastatin orally once a day, while the contrast groupreceived40mg of atorvastatin orally once a day. The biochemical changes in bloodlipids（TC, TG, HDL-C, LDL-C），blood count，liver function，kidney function andcreatine kinase was respectively measured,and also including adverse events wasrecorded before treatment started, and after4weeks and8weeks of treatment.Results:1. The levels of TG, TC and LDL-C were significantly decreased in4and8weeks aftertreatment (P<0.05) in two groups, and the levels of HDL-C was significantlyincreased(P<0.05). TC, TG, LDL-C level after8weeks were lowed by19.92%,32.75%,and34.47%in test group, while HDL-C level was increased by29.91%. TC, TG, LDL-C concentration after8weeks were lowed by18.23%,20%,30.23%in contrastgroup, while HDL-C level was increased by27.27%.2. The levels of TC, TG, LDL-C were significantly decreased in test group from4to8weeks after treatment, and HDL-C level was significantly increased (P <0.05). Thelevels of TC, TG were both significantly decreased in contrast group from4to8weeksafter treatment (P <0.05), but LDL-C or HDL-C change was not statistically significant(P>0.05).3. After8-week treatment, blood count, liver and kidney function, and creatine kinasewas recorded in two groups. Although ALT, AST in test group was more increased thanthat before treatment (P <0.05), they were still in the normal range. WBC in contrastgroup was in the normal reange, but it was more decreased than that before treatment(P <0.05). There had no significant adverse events in two groups.Conclusion:1. TC, TG and LDL-C are effectively reduced and HDL-C is significantly increased byjoint using of Zhibitai capsule with atorvastatin and separate double dose ofatorvastatin.2. There are no markedly difference in LDL-C, HDL-C level from4to8-week of theseparate double dose of atorvastatin group, which may suggest its efficacy onLDL-C and HDL-C yet to be tested for a long time.3. It may be proved that there is good safety and no significant adverse reaction in jointusing of Zhibitai capsule with atorvastatin and separate double dose of atorvastatin.